Skip to content

MiMedx Group MDXG Gross Profit

Gross Profit at other companies

IAR
Integra LifeSciencesIART
$216.98M+11.6%
Solventum logo
SolventumSOLV
$1.1B-1.5%
Vericel logo
VericelVCEL
$49.27M+35.8%
Enovis logo
EnovisENOV
$365.49M+10.0%
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
$57.61M+27.1%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Operating income-$16.0M-295%
Net income-$10.9M-255%
EPS (diluted)-$0.07-240%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%
Free cash flow$1.3M-73.4%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp
FCF margin17.8%-0.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Calculated from MiMedx Group’s reported figures.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's gross profit?
MiMedx Group (MDXG) reported gross profit of $41.62M in Q1 2026.
How has MiMedx Group's gross profit changed year-over-year?
MiMedx Group's gross profit decreased by 41.9% year-over-year, from $71.65M to $41.62M.
What is the long-term trend for MiMedx Group's gross profit?
Over 4 years (2021 to 2025), MiMedx Group's gross profit has grown at a 14.3% compound annual growth rate (CAGR), from $202.39M to $345.62M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.